Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out?

Company Performance - Progyny (PGNY) has seen a stock increase of 5.5% over the past month, reaching a new 52-week high of $28.49 [1] - Year-to-date, Progyny's stock has gained 6.8%, compared to 7.8% for the Zacks Medical sector and 10.9% for the Zacks Medical Services industry [1] Earnings and Revenue - Progyny has consistently beaten earnings estimates, with a reported EPS of $0.45 against a consensus estimate of $0.39 in its last earnings report [2] - For the current fiscal year, Progyny is expected to post earnings of $1.93 per share on revenues of $1.27 billion, with a year-over-year change of 7.22% [3] - For the next fiscal year, earnings are projected to be $2.11 per share on revenues of $1.39 billion, reflecting a year-over-year change of 9.24% [3] Valuation Metrics - Progyny's current valuation metrics show a trading multiple of 14.2X current fiscal year EPS estimates, below the peer industry average of 15.3X [7] - The stock trades at a trailing cash flow basis of 79.5X compared to the peer group's average of 11.2X, and has a PEG ratio of 0.85 [7] Zacks Rank and Style Scores - Progyny holds a Zacks Rank of 2 (Buy) due to a solid earnings estimate revision trend [8] - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A [6][8] Industry Comparison - In comparison to peers, Enhabit, Inc. (EHAB) also shows strong performance with a Zacks Rank of 2 (Buy) and a Value Score of A [9] - Enhabit, Inc. reported earnings that beat consensus estimates by 41.67%, with expected earnings of $0.53 per share on revenue of $1.06 billion for the current fiscal year [10]